Molecular analysis revealed alterations in the cell cycle control genes CDK4 and CDKN2A. In 2D cell cultures, we demonstrated that GSK126 and abemaciclib alone impaired the viability of our newly established GBM cultures. This evidence concerns the gene CDK4 and glioblastoma.